A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Celgene
Study ID
NCT06782490
Phase
PHASE2
Status
Recruiting

Conditions

  • Multiple Sclerosis Spasticity

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • BMS-986368 — DRUG
    Specified dose on specified days
  • Placebo — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity

Key Dates

Start date
Jun 5, 2025
Status verified
Jun 2026
Primary completion
May 26, 2027
Completion
Jun 9, 2027

Study Design

Enrollment
200 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Administration of BMS-986368 Dose A
  • Experimental: Administration of BMS-986368 Dose B
  • Experimental: Administration of BMS-986368 Dose C
  • Placebo Comparator: Placebo

Primary Outcome Measure

Change from baseline in Total Numeric-transformed Modified Ashworth Scale-Most Affected Lower Limb (TNmAS-MALL) score [ Time Frame: At week 6 ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
  • First line of the email MUST contain NCT # and Site #.

Locations (15)

FacilityCityStateZIPSite coordinators
Alabama Neurology AssociatesBirminghamAlabama35209
Emily Riser, Site 0033
205-803-2210
Perseverance Research Center,LLCScottsdaleArizona85253
Barry Hendin, Site 0050
602-258-3368
Local Institution - 0017AuroraColorado80045-
Aqualane Clinical ResearchNaplesFlorida34105
Matthew Baker, Site 0068
239-529-6780
USF HealthTampaFlorida33612
Derrick Robertson, Site 0015
813-974-6378
University of Kansas Medical CenterKansas CityKansas66160
Sharon Lynch, Site 0016
913-588-6980
Neurology Center of New EnglandFoxboroughMassachusetts02035
Andrew Taylor, Site 0049
781-551-5812
Local Institution - 0071SouthfieldMichigan48034
Site 0071
Washington University School of MedicineSt LouisMissouri63110
Robert Naismith, Site 0018
314-362-3293
University of Cincinnati Medical CenterCincinnatiOhio45219
Shahla Hosseini, Site 0002
412-427-7087
Local Institution - 0069ColumbusOhio43235-
Riverside Methodist HospitalColumbusOhio43214
Jacqueline Nicholas, Site 0039
614-566-1255
Local Institution - 0067PhiladelphiaPennsylvania19107
Site 0067
Hope NeurologyKnoxvilleTennessee37922
Sibyl Wray, Site 0003
865-218-6222
EvergreenHealth Medical CenterKirklandWashington98034
Theodore Brown, Site 0001
425-899-5385

Find similar trials in Birmingham, AL